Nektar Therapeutics (NKTR)

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar’s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

 

COMPANY ADDRESS
455 Mission Bay Boulevard South
San Francisco, California 94158
United States

COMPANY PHONE
415-482-5300

COMPANY WEBSITE



Get BioInvest's perspective on Nektar Therapeutic's CEO


Latest Company News

Could Nektar Therapeutics Be Worth More? Motley Fool - Mar 23, 2017 Nektar Therapeutics (NASDAQ:NKTR) is an intriguing commercial-stage biotech company that's just reported positive late-stage trial results for its pain-busting drug NKTR-181. Nektar Therapeutics (NKTR) Shares Bought by Thrivent Financial for Lutherans - The Cerbat Gem The Nektar Therapeutics (NKTR) PT Raised to $27.00 - Petro Global News 24 [...]
Thu, Mar 23, 2017 8:37:00 PM, Continue reading at the source
Digging Up the Facts on Nektar Therapeutics (NKTR) StockNewsJournal - Mar 21, 2017 Nektar Therapeutics (NKTR) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $22.11, up from yesterday's close by 42.65%. [...]
Tue, Mar 21, 2017 3:22:00 PM, Continue reading at the source
Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News Yahoo Finance - Mar 21, 2017 That is exactly what happened to CytomX Therapeutics on Monday, as Bristol-Myers Squibb Company and CytomX announced their expansion of the 2014 strategic collaboration agreement. [...]
Tue, Mar 21, 2017 1:30:00 PM, Continue reading at the source
Nektar Therapeutics (NKTR) Breaks into New 52-Week High on March 20 Session Equities.com - Mar 20, 2017 Shares of Nektar Therapeutics (NKTR) broke into a new 52-week high yesterday, hitting a peak of $22.32. Shares closed at $22.11 after opening at $18.78 for a move of 42.65%. [...]
Mon, Mar 20, 2017 9:30:00 PM, Continue reading at the source
Wall Street Cheers These Two Rising Stocks: Esperion Therapeutics Inc (ESPR ... Smarter Analyst - Mar 20, 2017 Esperion Therapeutics Inc (NASDAQ:ESPR) and Nektar Therapeutics (NASDAQ:NKTR) are skyrocketing with a fury today on back of major clinical strides forward that have investors today eagerly watching these needle-movers ascend up through the ... After-hours buzz: ESPR, NKTR, MMSI & more - CNBC 12 Biggest Mid-Day Gainers For Monday - Benzinga [...]
Mon, Mar 20, 2017 8:37:00 PM, Continue reading at the source
Why Nektar Therapeutics Inc. Is Rising Today Motley Fool - Mar 20, 2017 Nektar announced the results of its phase 3 SUMMIT-07 trial. This study was testing its compound NKTR-181 as a hopeful treatment for patients with moderate to severe chronic lower back pain. Nektar Therapeutics' stock jumps after positive results of its pain treatment drug - MarketWatch Nektar Therapeutics (NASDAQ:NKTR)'s Opioid-Based Drug Performs Well In Phase 3 ... - Journal Transcript [...]
Mon, Mar 20, 2017 3:51:00 PM, Continue reading at the source
Can this company's pain-fighting drug smash America's opioid crisis? San Francisco Business Times - Mar 20, 2017 Facing skepticism, the company says its drug enters the brain slowly, so pain-drug addicts don't get the euphoric rush they seek, but patients get effective pain relief. [...]
Mon, Mar 20, 2017 1:52:00 PM, Continue reading at the source
BRIEF-Nektar Therapeutics says NKTR-181 meets primary, secondary endpoints in ... Reuters - Mar 20, 2017 March 20 Stock futures pointed to a lower opening for Canada's main stock index on Monday after financial leaders of the world's biggest economies dropped a pledge to keep global trade free and open. [...]
Mon, Mar 20, 2017 11:48:00 AM, Continue reading at the source
Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics ... PR Newswire (press release) - Mar 13, 2017 Pre-market, Stock-Callers.com navigates the Biotechnology space with focus on Nektar Therapeutics (NASDAQ: NKTR), Seattle Genetics Inc. (NASDAQ: SGEN), Dynavax Technologies Corp. What are Analyst's Indicators for Nektar Therapeutics (NKTR), PDC Energy, Inc ... - The USA Commerce Nektar Therapeutics (NKTR) Shares Bought by Comerica Bank - BNB Daily (blog) [...]
Mon, Mar 13, 2017 12:11:00 PM, Continue reading at the source
Here's What's Behind Nektar Therapeutics' 20% Move Higher Motley Fool - Mar 2, 2017 Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases ... Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4 - Yahoo Finance Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results - PR Newswire (press release) [...]
Thu, Mar 02, 2017 10:08:00 PM, Continue reading at the source